hma

5-(N,N-Hexamethylene)-amiloride (5-HMA) is an amiloride derivative that inhibits TRPA1-mediated calcium signaling (IC50: 35 μM). It functions as an inhibitor of the Na+/H+ exchanger (NHE) with Ki values ranging from 0.013 to 2.4 μM for various NHE isoforms. Additionally, 5-HMA blocks ASIC3 channels by 51% at 20 μM.

Antiasthmatic Compound 1 is an antiasthmatic agent.

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

Asthma relating compound 1 is a potential anti-asthma compound.

hMAO-B-IN-4 is a selective, reversible and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B, IC50=0.067 μM, Ki= 0.03 μM, hMAO-A, IC50= 33.82 μM).

Rehmaneolignan A is a useful organic compound for research related to life sciences. The catalog number is T125420 and the CAS number is 2001061-00-1.

Daphmacrine is a natural product that can be used as a reference standard.

Compound 17k, also known as Antileishmanial agent-30, effectively inhibits Leishmania with an IC50 of 0.2 μM for L. donovani. It exhibits a CC50 of >100 μM and an SI of >500, indicating significant selectivity and potency.

hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 values of 424.1 nM and 177.9 nM, respectively. It has demonstrated neuroprotective effects in the MPTP-induced mouse model of Parkinson's Disease (PD).

Antileishmanial agent-31 (Compound p1) is a pyrazole derivative exhibiting antileishmanial activity with an IC50 of 35.53 μg/mL. Furthermore, Antileishmanial agent-31 demonstrates high stability and is applicable in studies focused on leishmaniasis treatment.

3,4-DHMA (3,4-Dihydroxymethamphetamine) TFA is an active metabolite of 3,4-MDMA.

Antileishmanial agent-33 (4e) is a hybrid compound of grandisin and machilin G, demonstrating moderate activity against promastigotes with an IC50 of 38.1 μM. In studies of cutaneous leishmaniasis (CL), Antileishmanial agent-33 (4e) has shown potential as an antileishmanial agent.

hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 0.11 µM. It operates by competitively binding to the active site of hMAO-B, thereby preventing the oxidative deamination of monoamines and reducing hydrogen peroxide production. Additionally, hMAO-B-IN-11 inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia. This compound holds potential for research in neurodegenerative diseases such as Parkinson's and Alzheimer's.

Antileishmanial agent-26 (Compound 69) is a guanidine-containing compound with activity against *Leishmania donovani*, exhibiting an IC50 value of 5.67 μM and a CC50 value of 3.79 μM in THP-1 cells. This compound is applicable for research in tropical diseases.

Antileishmanial agent-27 (compound 7j) is a benzothiazole-coumarin derivative. It acts as a competitive inhibitor of arginyl-tRNA synthetase (ArgRS). This compound demonstrates selectivity towards the Leishmania donovani ArgRS (LdArgRS) over the human counterpart (HsArgRS), with IC50 values of 1.2 μM and 19 μM, respectively. Additionally, Antileishmanial agent-27 exhibits favorable pharmacokinetic properties.

Antileishmanial agent-29 (Compound 110) is an orally active compound that exhibits antileishmanial properties. It can protect mice from Leishmania infection when administered orally at doses of 40 or 60 mg/kg over a period of 10 days.

hMAO-B-IN-8 (Compound 23) is an inhibitor of hMAO-B, eeAChE, COX-2, and 5-LOX, with IC50 values of 0.037 μM, 0.071 μM, 14.3 μM, and 0.59 μM, respectively. This compound is utilized in research related to Alzheimer's disease.

Rehmannioside C is an iridoid glucoside. Rehmannioside C has been isolated from Radix Rehmanniae Praeparata[1].

Rehmannioside A, a cyclic enol ether terpene glycoside extracted from the traditional Chinese medicine Dihuang, possesses neuroprotective activity and acts by inhibiting NF-κB and MAPK signaling pathways.

Rehmapicroside is a natural product of Rehmannia, Scrophulariaceae. The catalog number is T3S0462 and the CAS number is 104056-82-8. Rehmapicroside can be used as a reference standard.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

Nrf2-ARE/hMAO-B/QR2 modulator 1, a resveratrol derivative and multi-target-directed ligand (mtdl), activated the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibited hMAO-B and QR2（quinone reductase-2，NQO2) (IC 50 = 8.05 and 0.57 μM), and was able to promote hippocampal neurogenesis and exert neuroprotective and antioxidant effects in an Alzheimer's disease model.

hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor with IC50s of 2.5 μΜ for hMAO-B and 3.84 μΜ for MB-COMT. hMAO-B/MB-COMT-IN-1 protects cells from oxidative damage and can be utilized in neurodegenerative disease research, such as Parkinson's Disease (PD) [1].

Antileishmanial agent-8 (compound 18) exhibits potent and selective activity against Leishmania donovani (L. donovani) with an IC50 of 5.64 μM and relatively low cytotoxicity in L-6 cells with an IC50 of 73.9 μM [1].